Otávio Hallal Ferreira Raro

Otávio Hallal Ferreira Raro

Auto-generated profile, based on publicly available information

Otávio Hallal Ferreira Raro

Medical and Molecular Microbiology Unit—Department of Oncology, Microbiology, Immunology (OMI), Faculty of Science and Medicine, University of Fribourg , Chemin du Musée 18, Fribourg CH-1700

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
OROtávio Hallal Ferreira Raro
Otávio Hallal Ferreira Raro
PNPatrice Nordmann
Patrice Nordmann
MPManuel Dominguez Pino
Manuel Dominguez Pino
JFJacqueline Findlay
Jacqueline Findlay
LPLaurent Poirel
Laurent Poirel
Increasing occurrence of multidrug-resistant (MDR) and hypervirulent (hv) Klebsiella pneumoniae (MDR-hvKp) convergent clones is being observed. Those strains have the potential of causing difficult-to-treat infections in healthy adults with an increased capacity for mortality.

1 March 2017 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
OROtávio Hallal Ferreira Raro
Otávio Hallal Ferreira Raro
SGStephanie Wagner Gallo
Stephanie Wagner Gallo
CFCarlos Sanchez Ferreira
Carlos Sanchez Ferreira
SOSilvia Oliveira
Silvia Oliveira
Keywords: Acinetobacter baumannii; Antimicrobial resistance; Carbapenems; Hospital environmental contamination; Hospital infections

15 July 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
OROtávio Hallal Ferreira Raro
Otávio Hallal Ferreira Raro
RSRavena Maya Cardoso da Silva
Ravena Maya Cardoso da Silva
EFEdison Moraes Rodrigues Filho
Edison Moraes Rodrigues Filho
TSTeresa Cristina Teixeira Sukiennik
Teresa Cristina Teixeira Sukiennik
CSClaudio Stadnik
Claudio Stadnik
MPMaria Pérez-Vázquez
Maria Pérez-Vázquez
Objectives: Carbapenemase-producing Klebsiella pneumoniae (CP-Kp) is a major cause of infections in transplanted patients and has been associated with high mortality rates in this group. There is a lack of information about the Brazilian structure population of CP-Kp isolated from transplanted patients. By whole-genome sequencing (WGS), we analyzed phylogeny, resistome, virulome of CP-Kp isolates, and the structure of plasmids encoding blaKPC–2 and blaNDM–1 genes. Methods: One K. pneumoniae isolated from each selected transplanted patient colonized or infected by CP-Kp over a 16-month period in a hospital complex in Porto Alegre (Brazil) was submitted for WGS. The total number of strains sequenced was 80. The hospital complex in Porto Alegre comprised seven different hospitals. High-resolution SNP typing, core genome multilocus sequence typing (cgMLST), resistance and virulence genes inference, and plasmid reconstruction were performed in 80 CP-Kp. Results: The mortality rate of CP-Kp colonized or infected transplanted inpatients was 21.3% (17/80). Four CP-Kp epidemic clones were described: ST11/KPC-2, ST16/KPC-2, and ST15/NDM-1, all responsible for interhospital outbreaks; and ST437/KPC-2 affecting a single hospital. The average number of acquired resistance and virulence genes was 9 (range = 2–14) and 27 (range = 6–36), respectively. Two plasmids carrying the blaKPC–2 were constructed and belonged to IncN and IncM types. Additionally, an IncFIB plasmid carrying the blaNDM–1 was described. Conclusion: We detected intrahospital and interhospital spread of mobile structures and international K. pneumoniae clones as ST11, ST16, and ST15 among transplanted patients, which carry a significant range of acquired resistance and virulence genes and keep spreading across the world.

12 September 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
JFJacqueline Findlay
Jacqueline Findlay
RSRoberto Sierra
Roberto Sierra
OROtavio Hallal Ferreira Raro
Otavio Hallal Ferreira Raro
MAMarta Aires-de-Sousa
Marta Aires-de-Sousa
DADiego Andrey
Diego Andrey
PNPatrice Nordmann
Patrice Nordmann
Fosfomycin is a first-line treatment for uncomplicated urinary tract infections (UTIs) in several European countries, and it is increasingly becoming the treatment of choice globally. Resistance to fosfomycin in Escherichia coli can be exerted through several mechanisms, including the acquisition of fosfomycin-modifying enzymes, of which the FosA-type enzymes are the most common. This study analysed, both phenotypically and genotypically, an international collection of E. coli strains harbouring acquired fosA genes. Thirty-one fosA-positive E. coli isolates were obtained from both clinical and environmental sources, from seven countries (Portugal (n = 12), Switzerland (n = 9), China (n = 3), France (n = 2), Nepal (n = 2), South Africa (n = 2), Kuwait (n = 1)). MICs were determined according to EUCAST guidelines. Whole genome sequencing (WGS) was performed on 23 isolates, and complete fosA plasmid sequences were determined for 12. Conjugation assays were performed on seven isolates. All isolates exhibited high-level resistance to fosfomycin (64 to >256 mg/L). WGS of 23 isolates identified 17 sequence types (STs), and 16 harboured fosA3, four fosA4, two fosA8, and one fosA10. ESBLs, pAmpC, or carbapenemase genes were present in 15, four, and three isolates, respectively. The fosA plasmids of 12 isolates were determined and were diverse in size (∼67 kb to ∼235 kb), resistance gene carriage, and replicon types. Six fosA plasmids additionally carried ESBL or carbapenemase genes. Conjugation assays, performed on seven isolates harbouring diverse plasmids, identified that all were capable of being transmitted. This study highlights the necessity of the surveillance and close monitoring of fosfomycin resistance in E. coli, essential to maintain the optimal use of this treatment option.

24 July 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OROtávio Hallal Ferreira Raro
Otávio Hallal Ferreira Raro
LPLaurent Poirel
Laurent Poirel
MTMaurine Tocco
Maurine Tocco
PNPatrice Nordmann
Patrice Nordmann
Resistance genes can be genetically transmitted and exchanged between commensal and pathogenic bacterial species, and in different compartments including the environment, or human and animal guts (One Health concept). The aim of our study was to evaluate whether subdosages of antibiotics administered in veterinary medicine could enhance plasmid transfer and, consequently, resistance gene exchange in gut microbiota. Conjugation frequencies were determined with Escherichia coli strains carrying IncL- (blaOXA-48) or IncI1-type (blaCTX-M-1) plasmids subjected to a series of subinhibitory concentrations of antibiotics used in veterinary medicine, namely amoxicillin, ceftiofur, apramycin, neomycin, enrofloxacin, colistin, erythromycin, florfenicol, lincomycin, oxytetracycline, sulfamethazine, tiamulin and the ionophore narasin. Treatments with subinhibitory dosages were performed with and without supplementation with the antioxidant edaravone, known as a mitigator of the inducibility effect of several antibiotics on plasmid conjugation frequency (PCF). Expression of SOS-response associated genes and fluorescence-based reactive oxygen species (ROS) detection assays were performed to evaluate the stress oxidative response. Increased PCFs were observed for both strains when treating with florfenicol and oxytetracycline. Increased expression of the SOS-associated recA gene also occurred concomitantly, as well as increased ROS production. Addition of edaravone to the treatments reduced their PCF and also showed a decreasing effect on SOS and ROS responses for both plasmid scaffolds. We showed here that some antibiotics used in veterinary medicine may induce transfer of plasmid-encoded resistance and therefore may contribute to the worldwide spread of antibiotic resistance genes.

17 December 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
OROtávio Hallal Ferreira Raro
Otávio Hallal Ferreira Raro
JFJacqueline Findlay
Jacqueline Findlay
LPLaurent Poirel
Laurent Poirel
JDJean-Winoc Decousser
Jean-Winoc Decousser
PNPatrice Nordmann
Patrice Nordmann
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a critical global health threat due to its high mortality rates in infections, limited treatment options and resistance to last-resort antibiotics. Cefiderocol, a novel siderophore-conjugated cephalosporin, has emerged as a promising therapeutic agent against such infections. However, resistance to this antibiotic has already been reported. Objectives: To investigate whether the production of common carbapenemases affects cefiderocol susceptibility in A. baumannii and to identify the genetic mechanisms underlying resistance development. Methods: Using isogenic A. baumannii CIP 7010 strains carrying carbapenemase genes commonly identified in that species, namely blaNDM-1, blaOXA-23, blaOXA-40 or blaOXA-58, mutants were selected under increasing cefiderocol pressure. Mutants obtained were subjected to MIC determinations, WGS, complementation assays, real-time quantitative PCR (RT-qPCR) and fitness assays. Results: WGS of cefiderocol-resistant isolates revealed recurrent mutations in genes encoding the global regulators BfmS and OxyR, rather than in genes directly related to iron uptake, PBPs or β-lactamases. Complementation assays with WT bfmRS or oxyR resulted in a reversion to the parental strain cefiderocol MICs. RT-qPCR indicated that these global regulators reduced expression of piuA and pirA genes involved in iron uptake, and hence were associated with a previously unknown mechanism that results in resistance to cefiderocol. Conclusions: Global regulators BfmS and OxyR were responsible for decreasing the expression of piuA and pirA genes, thereby contributing to cefiderocol resistance. This evolutionary analysis enhances our understanding of the mechanisms underlying cefiderocol resistance and identifies potential molecular targets for the development of new therapeutics against CRAB.